BACK <<     
 

Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2012 Financial Results

MISSION VIEJO, CA--(Marketwire -05/14/12)- Aeolus Pharmaceuticals, Inc. (AOLS.OB) (OTC.BB: AOLS)

·         $2.2 million in revenue for second quarter 2012; $4.4 million in revenue for first half of fiscal year 2012

·         No-cost extension & modification of BARDA base year contract

·         BARDA exercises second year contract options

Aeolus Pharmaceuticals, Inc., a biotechnology company leveraging significant government funding to develop a platform of novel compounds in oncology and biodefense, announced today financial results for the three months and six months ended March 31, 2012.

The Company reported a net profit of approximately $2,763,000, or $0.05 per share, which includes a non-cash charge of approximately $3,324,000 related to decreases in the fair value of warrants that are included as a component of other income (expenses) in the statement of operations, for the three months ended March 31, 2012. This compares to a net profit of $3,778,000, or $0.06 per share, which includes a non-cash charge of approximately $4,746,000 related to decreases in the fair value of warrants that are included as a component of other income (expenses) in the statement of operations, for the three months ended March 31, 2011.

"The Company continues to make significant progress under our $118 million advanced research and development contract with BARDA, and BARDA confirmed their commitment to our program during the quarter with the exercise of two options valued at $9.1 million," stated John L. McManus, President and Chief Executive Officer. "With the base period and option funding in place we will have four key efficacy studies underway during the next 12 months, which we hope will provide additional evidence of AEOL 10150's ability to mitigate damage from radiation exposure."

Revenue for the three months ended March 31, 2012 was approximately $2,231,000, which compares to revenue of $785,000 for the three months ended March 31, 2011. The revenue is from the collaboration with BARDA announced on February 11, 2011.

Research and development expenses increased about $1,020,000 to approximately $1,927,000 for the three months ended March 31, 2012, from approximately $907,000 for the three months ended March 31, 2011. The increase is primarily attributable to work related to the BARDA Contract.

General and administrative expenses increased about $25,000, to approximately $865,000 for the three months ended March 31, 2012 from approximately $840,000 for the three months ended March 31, 2011.

As of March 31, 2012, the Company had approximately $390,000 in cash and cash equivalents and 62,237,551 common shares outstanding. The Company had accounts receivable of $2,479,000 and accounts payable of $3,376,000 on March 31, 2012. Aeolus has filed today with the SEC its Quarterly Report on Form 10-Q for the quarter ended March 31, 2012. Aeolus urges its investors to read this quarterly filing as well as its amended Annual Report on Form 10-K/A, also filed with the SEC, for further details concerning the Company. The Quarterly Report on Form 10-Q and the amended Annual Report on Form 10-K/A are also available on the Company's website, athttp://www.aeoluspharma.com.

About AEOL 10150

AEOL 10150 is a broad-spectrum catalytic antioxidant specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure. AEOL 10150 could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation in the treatment of oncology.

AEOL 10150 has already performed well in preclinical and non-clinical studies, was well-tolerated in two human clinical trials, and has demonstrated statistically significant survival efficacy in an acute radiation-induced lung injury model. The Company believes it could have a profound beneficial impact on people who have been exposed, or are about to be exposed, to high-doses of radiation, whether from cancer therapy or a nuclear event.

About Aeolus Pharmaceuticals

Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed for oncology indications, where it is used in combination with radiation therapy. It is also being developed, with funding by the US Government, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in oncology.

Forward-Looking Statements

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs, the Company's potential initiation of large efficacy studies, the potential impact of AEOL 10150 and the BARDA Contract. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and competition from other biopharmaceutical companies, and whether BARDA exercises one or more additional options under the BARDA Contract. Certain of these factors and others are more fully described in Aeolus' filings with the Securities and Exchange Commission, including, but not limited to, Aeolus' amended Annual Report on Form 10-K/A for the year ended September 30, 2011. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.

 

 

 

                        AEOLUS PHARMACEUTICALS, INC.                    CONDENSED CONSOLIDATED BALANCE SHEETS

                     (In thousands, except share data)

 

                                                 March 31,    September 30,

                                                    2012           2011

                                               -------------  -------------

                                                (Unaudited)

                    ASSETS

Current assets:

  Cash and cash equivalents                    $         390  $         518

  Accounts receivable                                  2,479          1,677

  Prepaids and other current assets                      210             63

                                               -------------  -------------

    Total current assets                               3,079          2,258

 

Investment in CPEC LLC                                    32             32

                                               -------------  -------------

    Total assets                               $       3,111  $       2,290

                                               =============  =============

 

     LIABILITIES AND STOCKHOLDERS' DEFICIT

Current liabilities:

  Accounts payable and accrued expenses        $       3,376  $       2,144

                                               -------------  -------------

    Total current liabilities                          3,376          2,144

 

Warrant liability                                     16,393         23,405

                                               -------------  -------------

    Total liabilities                                 19,769         25,549

 

Commitments and Contingencies

 

Stockholders' deficit:

  Preferred stock, $.01 par value per share,

   10,000,000 shares authorized:

  Series B nonredeemable convertible preferred

   stock, 1,600,000 and 600,000 shares

   authorized as of March 31, 2012 and

   September 30, 2011, respectively; 526,080

   and 526,080 shares issued and outstanding

   as of March 31, 2012 and September 30,

   2011, respectively                                      5              5

  Common stock, $.01 par value per share,

   200,000,000 shares authorized; 62,237,551

   and 60,470,718 shares issued and

   outstanding as of March 31, 2012 and

   September 30, 2011, respectively                      622            605

  Additional paid-in capital                         159,387        158,543

  Accumulated deficit                               (176,672)      (182,412)

                                               -------------  -------------

    Total stockholders' deficit                      (16,658)       (23,259)

                                               -------------  -------------

    Total liabilities and stockholders'

     deficit                                   $       3,111  $       2,290

                                               =============  =============

 

 

 

 

                        AEOLUS PHARMACEUTICALS, INC.               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                                (Unaudited)

                     (In thousands, except share data)

 

                                     Three Months Ended   Six Months Ended

                                          March 31,           March 31,

                                     ------------------  ------------------

                                       2012      2011      2012      2011

                                     --------  --------  --------  --------

Revenue

  Contract Revenue                   $  2,231  $    785  $  4,446  $    785

 

Costs and expenses:

  Research and development              1,927       907     3,998     1,097

  General and administrative              865       840     1,720     1,390

                                     --------  --------  --------  --------

    Total costs and expenses            2,792     1,747     5,718     2,487

                                     --------  --------  --------  --------

Loss from operations                     (561)     (962)   (1,272)   (1,702)

Non-cash financing charges and

 change in fair value of warrants       3,324     4,746     7,012    (2,456)

Interest income (expense), net             --        (6)       --       (21)

Other income (expense), net                --        --        --       337

                                     --------  --------  --------  --------

Net income (loss)                    $  2,763  $  3,778  $  5,740  $ (3,842)

                                     ========  ========  ========  ========

 

Net income (loss) per weighted share

 attributable to common

 stockholders:

  Basic                              $   0.05  $   0.06  $   0.10  $  (0.07)

                                     --------  --------  --------  --------

  Diluted                            $   0.04  $   0.03  $   0.08  $  (0.07)

                                     ========  ========  ========  ========

 

Weighted average common shares

 outstanding:

  Basic                                60,490    59,953    60,480    58,473

                                     --------  --------  --------  --------

  Diluted                              71,858   121,640    76,334    58,473

                                     ========  ========  ========  ========

 

 

 

 

                        AEOLUS PHARMACEUTICALS, INC.               CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                                (Unaudited)

                               (In thousands)

 

                                                         Six Months Ended

                                                             March 31,

                                                       --------------------

                                                          2012       2011

                                                       ---------  ---------

Cash flows from operating activities:

  Net income (loss)                                    $   5,740  $  (3,842)

  Adjustments to reconcile net loss to net cash used

   in operating activities:

    Stock-based compensation                                 347        421

    Change in fair value of warrants                      (7,012)     1,922

    Noncash interest and warrant costs                        --        534

    Change in assets and liabilities:

      Accounts receivable                                   (803)      (785)

      Prepaid and other assets                               (17)       (39)

      Accounts payable and accrued expenses                1,232       (136)

                                                       ---------  ---------

Net cash used in operating activities                       (513)    (1,925)

                                                       ---------  ---------

 

Cash flows provided by financing activities:

  Proceeds from issuance of common stock and warrants        400      1,000

  Costs related to the issuance of common stock and

   warrants                                                  (15)       (13)

  Proceeds from exercise of warrants                          --        269

                                                       ---------  ---------

Net cash provided by financing activities                    385      1,256

                                                       ---------  ---------

 

Net decrease in cash and cash equivalents                   (128)      (669)

Cash and cash equivalents at beginning of period             518      2,355

                                                       ---------  ---------

Cash and cash equivalents at end of period             $     390  $   1,686

                                                       =========  =========

 

Supplemental disclosure of non-cash financing

 activities:

Common stock issued for short-term receivable          $     130  $      --

                                                       =========  =========

 

 

Contact:


Russell Skibsted
Sr. Vice President and Chief Financial Officer
Aeolus Pharmaceuticals, Inc.
1-(949) 481-9825 

 


 

 
     
 
 
Copyright © 2001-2017. All Rights Reserved.